T

Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119

Watchlist Manager
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Watchlist
Price: 18.48 CNY -3.25%
Market Cap: 8.6B CNY
Have any thoughts about
Tianjin Ringpu Bio-Technology Co Ltd?
Write Note

Net Margin
Tianjin Ringpu Bio-Technology Co Ltd

17.6%
Current
19%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17.6%
=
Net Income
424m
/
Revenue
2.4B

Net Margin Across Competitors

Country CN
Market Cap 8.6B CNY
Net Margin
18%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 756.3B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 349.7B USD
Net Margin
17%
Country US
Market Cap 251.6B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.6B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.4B USD
Net Margin
7%
No Stocks Found

Tianjin Ringpu Bio-Technology Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Tianjin Ringpu Bio-Technology Co., Ltd. has carved a niche for itself as a formidable player in the animal health and nutrition industry. Founded in 1998, the company has steadily expanded its portfolio, offering a diverse range of products designed to enhance the health and productivity of livestock and pets. Ringpu's operations are tightly integrated across research, development, production, and sales of veterinary vaccines, medicines, and feed additives. By leveraging cutting-edge biotechnology, Ringpu devises innovative solutions that meet the rigorous standards of animal health care. Its research facilities are at the forefront of developing vaccines that guard against prevalent livestock and pet diseases, ensuring that its offerings remain both effective and relevant. The company's ability to generate revenue hinges on its extensive distribution network and the strategic partnerships it has fostered within China and globally. Ringpu sells its products through a well-established sales force that connects with farmers, livestock producers, and veterinary clinics, providing not just products but also comprehensive health management solutions. Additionally, the company invests heavily in fostering relationships with academic institutions and research bodies, ensuring a steady pipeline of groundbreaking discoveries and innovations. This approach not only bolsters the company's reputation in the industry but also guarantees a sustained stream of income as more clients turn to Ringpu for reliable and sophisticated animal healthcare solutions.

Intrinsic Value
24.96 CNY
Undervaluation 26%
Intrinsic Value
Price
T

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17.6%
=
Net Income
424m
/
Revenue
2.4B
What is the Net Margin of Tianjin Ringpu Bio-Technology Co Ltd?

Based on Tianjin Ringpu Bio-Technology Co Ltd's most recent financial statements, the company has Net Margin of 17.6%.